Adding Keytruda to Chemo Slows Worsening in Advanced TNBC with PD-L1 Markers, Trial Finds

Adding Keytruda to Chemo Slows Worsening in Advanced TNBC with PD-L1 Markers, Trial Finds

First-line treatment with Keytruda (pembrolizumab) and chemotherapy prolongs the time without disease worsening in people with advanced triple-negative breast cancer (TNBC) whose tumors are positive for the marker PD-L1, an interim analysis of the KEYNOTE-355 trial shows.

The analysis, conducted by an independent committee, confirmed that one of the trial's primary goals was met — time to disease progression or death increased significantly and in a clinically meaningful way, compared to chemotherapy alone, in patients with PD-L1 in more than 10% of the cells in their tumors (including tumor cells and immune cells). Keytruda's safety profile remains consistent with prior studies, and no new safety signals were observed. Based on the committee's recommendation, KEYNOTE-355 will continue as planned to evaluate other primary and secondary trial measures. “Triple-negative breast cancer is an aggressive malignancy. It is very encouraging that Keytruda in combination with chemotherapy has now demonstrated positive results as both a first-line treatment in the metastatic setting with this trial, and as neoadjuvant therapy in the KEYNOTE-522 trial,” Roger M. Perlmutter, president of Merck Research Laboratories, said in a
Subscribe or to access all post and page content.